Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Southern Alberta Cancer Research Institute, Clark H. Smith Brain Tumor Center, Calgary, Alberta, Canada.
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):103-17. doi: 10.1016/j.cytogfr.2010.04.001. Epub 2010 May 18.
The concept of oncolytic viral therapy has a century-old history, but only within the last 20 years have oncolytic viruses been considered for the treatment of brain cancers. Viruses such as herpes, measles, and vaccinia have all been known to cause devastating cases of neurological disease in humans, yet these 'scourges' are now being harnessed in such a way that they prove very useful as cancer therapeutics. There have been 8 formal clinical trials and 3 case studies using oncolytic viruses to treat malignant glioma patients. Although some success has been reached with oncolytic therapy, overall it has fallen short of expectations. In this review we analyze the results of these trials and bring to light some of the limitations and pitfalls of this therapy, as well as present some promising preclinical work that has been proposed to circumvent such problems.
溶瘤病毒治疗的概念已有百年历史，但直到最近 20 年，溶瘤病毒才被考虑用于治疗脑癌。疱疹、麻疹和牛痘等病毒在人类中都曾导致严重的神经疾病，但现在这些“祸害”正被利用，成为非常有用的癌症治疗方法。已经有 8 项使用溶瘤病毒治疗恶性神经胶质瘤患者的正式临床试验和 3 项病例研究。尽管溶瘤治疗取得了一定的成功，但总体而言，其结果仍低于预期。在这篇综述中，我们分析了这些试验的结果，揭示了该疗法的一些局限性和缺陷，并介绍了一些有前景的临床前工作，这些工作旨在解决这些问题。
